Bryan Yoon
Operationeel Directeur bij TERNS PHARMACEUTICALS, INC.
Vermogen: 552 559 $ op 31-05-2024
Actieve functies van Bryan Yoon
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
TERNS PHARMACEUTICALS, INC. | Operationeel Directeur | 01-11-2020 | - |
Algemeen Adviseur | 01-11-2020 | - | |
Bedrijfssecretaris | 01-01-2021 | - |
Loopbaan van Bryan Yoon
Eerdere bekende functies van Bryan Yoon
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
LOGICBIO THERAPEUTICS, INC. | Hoofd Administratief Officier | 01-11-2019 | 06-11-2020 |
Algemeen Adviseur | 01-11-2019 | 06-11-2020 | |
Bedrijfssecretaris | 01-11-2019 | 06-11-2020 | |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Directeur/Bestuurslid | 08-01-2018 | 07-06-2019 |
NIGHTSTAR THERAPEUTICS PLC | Algemeen Adviseur | 01-11-2017 | 01-06-2019 |
Bedrijfssecretaris | 01-02-2018 | 01-06-2019 | |
INTERCEPT PHARMACEUTICALS, INC. | Algemeen Adviseur | 01-01-2013 | 01-11-2017 |
Bedrijfssecretaris | 01-01-2013 | 01-11-2017 |
Opleiding van Bryan Yoon
Cornell University | Graduate Degree |
The University of Michigan Law School | Graduate Degree |
Statistieken
Internationaal
Verenigde Staten | 6 |
Verenigd Koninkrijk | 3 |
Operationeel
General Counsel | 4 |
Corporate Secretary | 4 |
Graduate Degree | 2 |
Sectoraal
Health Technology | 5 |
Consumer Services | 3 |
Health Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
TERNS PHARMACEUTICALS, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Nightstar Therapeutics Ltd.
Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Health Services |
LogicBio Therapeutics, Inc.
LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
- Beurs
- Insiders
- Bryan Yoon
- Ervaring